Cargando…

The Novel Methylation Biomarker SCARA5 Sensitizes Cancer Cells to DNA Damage Chemotherapy Drugs in NSCLC

BACKGROUND: Scavenger Receptor Class A Member 5 (SCARA5), also known as TESR, is expressed in various tissues and organs and participates in host defense. Recent studies have found SCARA5 to produce an anti-tumor effect for multiple tumors, although the mechanistic basis for the effect is unknown. M...

Descripción completa

Detalles Bibliográficos
Autores principales:	Peng, Qi, Liu, Yan, Kong, Xuehua, Xian, Jie, Ye, Lin, Yang, Li, Guo, Shuliang, Zhang, Yan, Zhou, Lan, Xiang, Tingxiu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8213031/ https://www.ncbi.nlm.nih.gov/pubmed/34150631 http://dx.doi.org/10.3389/fonc.2021.666589

Ejemplares similares

Identification of SCARA3 with potential roles in metabolic disorders
por: Peng, Hui, et al.
Publicado: (2020)

Decreased expression of SCARA5 predicts a poor prognosis in melanoma using bioinformatics analysis
por: Ni, Qinggan, et al.
Publicado: (2023)

Construction of inflammatory associated risk gene prognostic model of NSCLC and its correlation with chemotherapy sensitivity
por: Gong, Yange, et al.
Publicado: (2023)

SCARA5 Is Overexpressed in Prostate Cancer and Linked to Poor Prognosis
por: Flockerzi, Fidelis Andrea, et al.
Publicado: (2023)

Methylation analysis of p16, SLIT2, SCARA5, and Runx3 genes in hepatocellular carcinoma
por: Sun, Gaofeng, et al.
Publicado: (2017)

Chemotherapy in Metastatic NSCLC – New Regimens (Pemetrexed, Nab-Paclitaxel)
por: Blais, Normand, et al.
Publicado: (2014)

Prospective Exploratory Analysis of Angiogenic Biomarkers in Peripheral Blood in Advanced NSCLC Patients Treated With Bevacizumab Plus Chemotherapy: The ANGIOMET Study
por: Jantus-Lewintre, Eloisa, et al.
Publicado: (2021)

Predictive value of DNA methylation in the efficacy of chemotherapy for gastric cancer
por: Li, Ye, et al.
Publicado: (2023)

Erratum: Chemotherapy in Metastatic NSCLC – New Regimens (Pemetrexed, Nab-Paclitaxel)
Publicado: (2014)

Editorial: Emerging Biomarkers for NSCLC: Recent Advances in Diagnosis and Therapy
por: Malapelle, Umberto, et al.
Publicado: (2021)

Association of sarcopenia with survival in advanced NSCLC patients receiving concurrent immunotherapy and chemotherapy
por: Bolte, Fabian J., et al.
Publicado: (2022)

Functional changes of the prefrontal cortex, insula, caudate and associated cognitive impairment (chemobrain) in NSCLC patients receiving different chemotherapy regimen
por: Liu, Siwen, et al.
Publicado: (2022)

Radiolabeled EGFR TKI as predictive imaging biomarkers in NSCLC patients – an overview
por: Van De Stadt, Eveline, et al.
Publicado: (2022)

SCARA5 plays a critical role in the commitment of mesenchymal stem cells to adipogenesis
por: Lee, Hyemin, et al.
Publicado: (2017)

SCARA5 inhibits gastric cancer progression via epithelial-mesenchymal transition suppression
por: Zhang, Hangyu, et al.
Publicado: (2021)

Highly Expressing SCARA5 Promotes Proliferation and Migration of Esophageal Squamous Cell Carcinoma
por: Jumai, Kawuli, et al.
Publicado: (2022)

Pembrolizumab Plus Chemotherapy or Anlotinib vs. Pembrolizumab Alone in Patients With Previously Treated EGFR-Mutant NSCLC
por: Chen, Ya, et al.
Publicado: (2021)

SCARA3 inhibits cell proliferation and EMT through AKT signaling pathway in lung cancer
por: Kim, Jeeho, et al.
Publicado: (2022)

SCARA5 induced ferroptosis to effect ESCC proliferation and metastasis by combining with Ferritin light chain
por: Liu, Yanqun, et al.
Publicado: (2022)

GEO Data Mining Identifies OLR1 as a Potential Biomarker in NSCLC Immunotherapy
por: Liu, Bin, et al.
Publicado: (2021)

Seven DNA Methylation Biomarker Prediction Models for Monitoring the Malignant Progression From Advanced Adenoma to Colorectal Cancer
por: Wang, Wei, et al.
Publicado: (2022)

Clickable Cisplatin Derivatives as Versatile Tools to Probe the DNA Damage Response to Chemotherapy
por: Moretton, Amandine, et al.
Publicado: (2022)

Pembrolizumab Alone or Combined With Chemotherapy in Advanced NSCLC With PD-L1 ≥50%: Results of a Retrospective Study
por: Chen, Ya, et al.
Publicado: (2021)

A Diagnostic Panel of DNA Methylation Biomarkers for Lung Adenocarcinoma
por: Shen, Nan, et al.
Publicado: (2019)

Gene Promoter-Methylation Signature as Biomarker to Predict Cisplatin-Radiotherapy Sensitivity in Locally Advanced Cervical Cancer
por: Contreras-Romero, Carlos, et al.
Publicado: (2022)

Inhibition of SMYD2 Sensitized Cisplatin to Resistant Cells in NSCLC Through Activating p53 Pathway
por: Shang, Lei, et al.
Publicado: (2019)

L-Ferritin Binding to Scara5: A New Iron Traffic Pathway Potentially Implicated in Retinopathy
por: Mendes-Jorge, Luísa, et al.
Publicado: (2014)

Suppression of SCARA5 by Snail1 is essential for EMT-associated cell migration of A549 cells
por: Liu, J, et al.
Publicado: (2013)

Neurofuzzy c-Means Network-Based SCARA Robot for Head Gimbal Assembly (HGA) Circuit Inspection
por: Kiatwanidvilai, Somyot, et al.
Publicado: (2018)

Comprehensive Comparison Between Adjuvant Targeted Therapy and Chemotherapy for EGFR-Mutant NSCLC Patients: A Cost-Effectiveness Analysis
por: Li, Wenqian, et al.
Publicado: (2021)

SRC and MEK Co-inhibition Synergistically Enhances the Anti-tumor Effect in Both Non-small-cell Lung Cancer (NSCLC) and Erlotinib-Resistant NSCLC
por: Yuan, Man, et al.
Publicado: (2019)

Pretreatment Neutrophil-to-Lymphocyte Ratio (NLR) May Predict the Outcomes of Advanced Non-small-cell Lung Cancer (NSCLC) Patients Treated With Immune Checkpoint Inhibitors (ICIs)
por: Li, Ye, et al.
Publicado: (2020)

The Landscape of Immunotherapy Resistance in NSCLC
por: Frisone, Daniele, et al.
Publicado: (2022)

PCDH20 inhibits esophageal squamous cell carcinoma proliferation and migration by suppression of the mitogen-activated protein kinase 9/AKT/β-catenin pathway
por: Ning, Yijiao, et al.
Publicado: (2022)

Cost-effectiveness analysis of adjuvant therapy with atezolizumab in Chinese patients with stage IB-IIIA resectable NSCLC after adjuvant chemotherapy
por: Chen, Ping, et al.
Publicado: (2022)

Effect of depression disorder on the efficacy and quality of life of first-line chemotherapy combined with immunotherapy in oncogene-driver negative NSCLC patients
por: Li, Wen, et al.
Publicado: (2022)

Immunotherapy combined with rh-endostatin improved clinical outcomes over immunotherapy plus chemotherapy for second-line treatment of advanced NSCLC
por: Huang, Hongxiang, et al.
Publicado: (2023)

Cytological DNA methylation for cervical cancer screening: a validation set
por: Kong, Linghua, et al.
Publicado: (2023)

The Sensitivity Prediction of Neoadjuvant Chemotherapy for Gastric Cancer
por: Sun, Juan, et al.
Publicado: (2021)

Research Progress of Anti-PD-1/PD-L1 Immunotherapy Related Mechanisms and Predictive Biomarkers in NSCLC
por: Bie, Fenglong, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_jhiqj51t5ih8r8q9que5sgkdr2